InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Allogene Therapeutics, Inc.

ALLO Clue Score24
United States Fiscal year ends December CIK 0001737287
$1.46 +4.29% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.46 −89.15% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 11 Oct 2018. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2018Operating income−192.8Net income−211.5Fiscal year 2019Revenue0.0Operating income−202.0Net income−184.6EPS, diluted−1.83Fiscal year 2020Revenue0.0Operating income−258.2Net income−316.4EPS, diluted−2.63Fiscal year 2021Revenue114.1Operating income−180.2Net income−182.1EPS, diluted−1.34Fiscal year 2022Revenue0.2 −99.9%Operating income−335.5Net income−340.4EPS, diluted−2.38Fiscal year 2023Revenue0.1 −39.1%Operating income−327.7Net income−327.3EPS, diluted−2.09Fiscal year 2024Revenue0.0 −76.8%Operating income−273.2Net income−257.6EPS, diluted−1.32Fiscal year 2025Revenue0.0 −100.0%Operating income−209.3Net income−190.9EPS, diluted−0.87
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a 0.0 0.0 114.1 0.2 0.1 0.0 0.0
Growth −99.9% −39.1% −76.8% −100.0%
Operating income −192.8 −202.0 −258.2 −180.2 −335.5 −327.7 −273.2 −209.3
Net income −211.5 −184.6 −316.4 −182.1 −340.4 −327.3 −257.6 −190.9
Growth
EPS, diluted n/a −1.83 −2.63 −1.34 −2.38 −2.09 −1.32 −0.87
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Operating margin−157.9%Net margin−159.6%Free cash flow margin−180.8%Fiscal year 2022Operating margin−215,087.2%Net margin−218,214.1%Free cash flow margin−144,685.9%Fiscal year 2023Operating margin−344,986.3%Net margin−344,489.5%Free cash flow margin−251,841.1%Fiscal year 2024Operating margin−1,241,813.6%Net margin−1,170,863.6%Free cash flow margin−913,609.1%Fiscal year 2025
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a −157.9% −215,087.2% −344,986.3% −1,241,813.6% n/a
Net margin n/a n/a n/a −159.6% −218,214.1% −344,489.5% −1,170,863.6% n/a
Free cash flow margin n/a n/a n/a −180.8% −144,685.9% −251,841.1% −913,609.1% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2018Operating cash flow−44.7Capital expenditure−3.2Free cash flow−47.9Fiscal year 2019Operating cash flow−137.4Capital expenditure−50.8Free cash flow−188.1Fiscal year 2020Operating cash flow−115.1Capital expenditure−66.0Free cash flow−181.1Fiscal year 2021Operating cash flow−184.8Capital expenditure−21.4Free cash flow−206.3Fiscal year 2022Operating cash flow−220.5Capital expenditure−5.2Free cash flow−225.7Fiscal year 2023Operating cash flow−237.7Capital expenditure−1.5Free cash flow−239.2Fiscal year 2024Operating cash flow−200.3Capital expenditure−0.7Free cash flow−201.0Fiscal year 2025Operating cash flow−149.2Capital expenditure−0.4Free cash flow−149.6
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −44.7 −137.4 −115.1 −184.8 −220.5 −237.7 −200.3 −149.2
Capital expenditure −3.2 −50.8 −66.0 −21.4 −5.2 −1.5 −0.7 −0.4
Free cash flow −47.9 −188.1 −181.1 −206.3 −225.7 −239.2 −201.0 −149.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2018Cash92.4Shareholders’ equity703.2Fiscal year 2019Cash175.1Shareholders’ equity629.0Fiscal year 2020Cash183.4Shareholders’ equity1,013.5Fiscal year 2021Cash173.3Shareholders’ equity925.2Fiscal year 2022Cash61.9Shareholders’ equity666.9Fiscal year 2023Cash83.2Shareholders’ equity512.2Fiscal year 2024Cash75.2Shareholders’ equity422.2Fiscal year 2025Cash51.7Shareholders’ equity292.5
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 92.4 175.1 183.4 173.3 61.9 83.2 75.2 51.7
Shareholders’ equity 703.2 629.0 1,013.5 925.2 666.9 512.2 422.2 292.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a 0.0 0.0 114.1 0.2 0.1 0.0 0.0
Growth −99.9% −39.1% −76.8% −100.0%
151.9 144.5 193.0 220.2 256.4 242.9 192.3 150.2
41.0 57.5 65.3 74.1 79.3 71.7 65.2 56.8
−192.8 −202.0 −258.2 −180.2 −335.5 −327.7 −273.2 −209.3
Growth
−211.6 −184.9 −250.2 −257.0 n/a −327.3 −257.1 −190.9
−0.1 −0.3 0.0 0.0 0.0 0.0 0.4 0.0
−211.5 −184.6 −316.4 −182.1 −340.4 −327.3 −257.6 −190.9
Growth
Per share
n/a −1.83 −2.63 −1.34 −2.38 −2.09 −1.32 −0.87
n/a −1.83 −2.63 −1.34 −2.38 −2.09 −1.32 −0.87
Growth
n/a 101.1 120.4 135.8 143.1 156.9 194.8 220.6
n/a 101.1 120.4 135.8 143.1 156.9 194.8 220.6
Growth +19.1% +12.8% +5.4% +9.6% +24.1% +13.2%

Five years in brief

Worked out from the figures above, not from a press release
  • The diluted share count rose 83.3% in five years, which is dilution.
  • A net loss in 8 of 8 years on file.